Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights

The treatment of non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma (LUAD), represents a significant oncological challenge due to its aggressive behavior, high metastatic potential and poor prognosis. HER2 mutation is a rare but critical oncogenic driver associated with resistance...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Guanbin Huang, Tongtong Xia, Dongxiao Yang, Muwen Lin, Yiping Luo, Yuchan Li, Hualin Chen
Format:	Artigo
Sprog:	Inglês
Udgivet:	Frontiers Media S.A. 2025-04-01
Serier:	Frontiers in Pharmacology
Fag:	HER2-mutant NSCLC trastuzumab deruxtecan antibody-drug conjugate first line treatment central nervous system metastases
Online adgang:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1564834/full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!